Back to Results

Elixxer Ltd (ELIXF)

Elixxer Ltd. is a common stock listing on OTC Markets under the symbol ELIX.F. The company is based in Montreal, Canada, and the available description indicates that it does not have significant operations. Its stated business focus is on investing in the cultivation and production of cannabis products. As a common equity security, the listing represents ownership in the company rather than a fund, debt instrument, or other specialized security type.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-ELIX.F
$0.030
-11.8% Downside
Fair
Not available
Not available
Weak
0.0%
December 1, 2026
3.191 M
9.787 M
70.2%
15.4%
-374.3
26.2%
Valuation • Fair Value

Elixxer Ltd (OTC-ELIX.F) Fair Value by Valuation Model

Review the available estimates for Elixxer Ltd (OTC-ELIX.F), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.030

Estimated downside of 11.8% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.030

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 3 available valuation references for Elixxer Ltd (OTC-ELIX.F) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Elixxer Ltd (OTC-ELIX.F)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Elixxer Ltd (OTC-ELIX.F) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Elixxer Ltd (OTC-ELIX.F)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

2

Weak quality score that deserves closer review.

Altman Z-Score

-374.3

Lower score that deserves closer risk review.

FCF / Net Income

26.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Elixxer Ltd (OTC-ELIX.F). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Elixxer Ltd (OTC-ELIX.F)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

December 1, 2026

Days to Earnings

70

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Elixxer Ltd (OTC-ELIX.F), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Buy

The 15-minute technical read for Elixxer Ltd (OTC-ELIX.F) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Elixxer Ltd (OTC-ELIX.F) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Elixxer Ltd (OTC-ELIX.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Elixxer Ltd (OTC-ELIX.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for Elixxer Ltd (OTC-ELIX.F) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Elixxer Ltd (OTC-ELIX.F) Stock FAQ

Data-supported answers about Elixxer Ltd (OTC-ELIX.F), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.030
Estimated downside 11.8%
Valuation Rating
Overvalued
Estimated downside of 11.8%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Elixxer Ltd (OTC-ELIX.F) is $0.030. This implies an estimated downside of 11.8% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 11.8% versus the current market price.

The current financial health read for Elixxer Ltd (OTC-ELIX.F) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Elixxer Ltd (OTC-ELIX.F) is December 1, 2026.

The latest available data indicates no current dividend yield for Elixxer Ltd (OTC-ELIX.F).

The current market capitalization listed for Elixxer Ltd is 3.191 M.

The current enterprise value listed for Elixxer Ltd is 9.787 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Elixxer Ltd is OTC-ELIX.F, and the stock is listed on OTC Markets.

Elixxer Ltd (OTC-ELIX.F) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Elixxer Ltd is 70.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Elixxer Ltd is 15.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Capital Markets Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

MS NYSE Morgan Stanley Fair Value Fair Market Cap 314.4 B
MS_PA NYSE Morgan Stanley Pa ADR Fair Value Undervalued Market Cap 314.4 B
MS_PE NYSE Morgan Stanley Pe ADR Fair Value Undervalued Market Cap 314.4 B
MS_PF NYSE Morgan Stanley Pf ADR Fair Value Undervalued Market Cap 314.4 B
MS_PI NYSE Morgan Stanley Pi ADR Fair Value Undervalued Market Cap 314.4 B
GS NYSE Goldman Sachs Group Inc Fair Value Fair Market Cap 287.5 B
BLK NYSE BlackRock Inc Fair Value Fair Market Cap 173.5 B
SCHW NYSE Charles Schwab Corp Fair Value Undervalued Market Cap 173.5 B
IBKR NASDAQ Interactive Brokers Group Inc Fair Value Fair Market Cap 158 B
BX NYSE Blackstone Inc Fair Value Undervalued Market Cap 155.3 B
UBS NYSE UBS Group AG Fair Value Fair Market Cap 150.5 B
SPGI NYSE S&P Global Inc Fair Value Fair Market Cap 118.6 B
HOOD NASDAQ Robinhood Markets Inc Fair Value Overvalued Market Cap 111.7 B
BNY NYSE Bank of New York Mellon Corp Fair Value Fair Market Cap 101.9 B
CME NASDAQ CME Group Inc Fair Value Fair Market Cap 96.083 B
KKR NYSE KKR & Co LP Fair Value Fair Market Cap 88.363 B
ICE NYSE Intercontinental Exchange Inc Fair Value Fair Market Cap 85.854 B
BN NYSE Brookfield Corp Fair Value Fair Market Cap 84.512 B
MCO NYSE Moodys Corporation Fair Value Fair Market Cap 81.265 B
BAM NYSE Brookfield Asset Management Inc Fair Value Fair Market Cap 73.573 B